Dr. Karim Fizazi presented “Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal, between October 14th and 16th, 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi, and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: castration resistant prostate cancer, ADT, Abiraterone, Enzalutamide, taxanes
How to cite: Fizazi, Karim. “Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer” Grand Rounds in Urology. October 14-16, 2016. Accessed Nov 2024. https://dev.grandroundsinurology.com/update-mechanisms-resistance-castration-resistant-prostate-cancer
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal, between the 14th and 16th of October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi, and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Dr. Karim Fizazi is a medical oncologist, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France, and a Professor of Oncology at the University of Paris-Sud. Dr. Fizazi received his medical degree in 1995 and completed a Fellowship in Medical Oncology in 1997. He obtained a PhD in Molecular Oncology in 2003. Dr. Fizazi has been involved in many Phase I, II, and III clinical trials as a national or global coordinating investigator. These include GETUG 12 (a 400-patient national Phase III trial testing docetaxel in high-risk localized prostate cancer), GETUG 13 (an international trial in poor-prognosis non-seminomatous germ-cell tumors), and numerous industry-sponsored clinical trials, including the denosumab versus zoledronic acid pivotal study, the TAK700 post-docetaxel and the cabazitaxel-OGX-011 large Phase III trials in castrate-resistant prostate cancer, and the abiraterone Latitude Phase III trial in patients with hormone-naïve metastatic prostate cancer. Dr. Fizazi also coordinated the Peace-1 Phase III trial testing the role of abiraterone acetate and of radiotherapy directed to the prostate in patients with newly diagnosed metastatic prostate cancer treated with ADT, as well as the Peace-2 Phase III trial testing cabazitaxel and pelvic lymph node irradiation in patients with high-risk localized prostate cancer treated with ADT-radiotherapy.
